Intellectual property issues of immune checkpoint inhibitors

被引：8

作者：

Storz, Ulrich ^{[1
,2
]}

机构：

[1] Michalski, Dusseldorf, Germany

[2] Huttermann Patent Attorneys, Dusseldorf, Germany

来源：

MABS | 2016年 / 8卷 / 01期

关键词：

antibody; CTLA4; Immune checkpoint inhibitors; Keytruda; Opdivo; patent; PD1; PD-L1; Yervoy; B7; FAMILY; CTLA-4; ANTIBODIES; CP-675,206; MELANOMA; THERAPY; MEMBER; B7-H1; PD-1;

D O I：

10.1080/19420862.2015.1107688

中图分类号：

R-3 [医学研究方法]; R3 [基础医学];

学科分类号：

1001 ;

摘要：

Immune checkpoint inhibitors are drugs that interfere with tumor escape responses. Some members of this class are already approved, and expected to be blockbusters in the future. Many companies have developed patent activities in this field. This article focuses on the patent landscape, and discusses key players and cases related to immune checkpoint inhibitors.

引用

页码：10 / 26

页数：17

共 50 条

[1] Immune checkpoint inhibitors for the treatment of melanoma
Sabbatino, Francesco
Liguori, Luigi
Pepe, Stefano
Ferrone, Soldano
EXPERT OPINION ON BIOLOGICAL THERAPY, 2022, 22 (05) : 563 - 576
[2] Neurologic complications of immune checkpoint inhibitors
Fellner, Avi
Makranz, Chen
Lotem, Michal
Bokstein, Felix
Taliansky, Alisa
Rosenberg, Shai
Blumenthal, Deborah T.
Mandel, Jacob
Fichman, Suzana
Kogan, Elena
Steiner, Israel
Siegal, Tali
Lossos, Alexander
Yust-Katz, Shlomit
JOURNAL OF NEURO-ONCOLOGY, 2018, 137 (03) : 601 - 609
[3] Cutaneous adverse effects of the immune checkpoint inhibitors
Collins, Lindsey K.
Chapman, M. Shane
Carter, Joi B.
Samie, Faramarz H.
CURRENT PROBLEMS IN CANCER, 2017, 41 (02) : 125 - 128
[4] Biomarkers for Response of Melanoma Patients to Immune Checkpoint Inhibitors: a Systematic Review
Jessurun, Charissa A. C.
Vos, Julien A. M.
Limpens, Jacqueline
Luiten, Rosalie M.
FRONTIERS IN ONCOLOGY, 2017, 7
[5] The Use of Phytochemicals to Improve the Efficacy of Immune Checkpoint Inhibitors: Opportunities and Challenges
Guven, Deniz Can
Sahin, Taha Koray
Rizzo, Alessandro
Ricci, Angela Dalia
Aksoy, Sercan
Sahin, Kazim
APPLIED SCIENCES-BASEL, 2022, 12 (20):
[6] Immune Checkpoint Inhibitors and the Heart
Mocan-Hognogi, Diana Larisa
Tranca, Sebastian
Farcas, Anca Daniela
Mocan-Hognogi, Radu Florin
Parvu, Andrada Viorica
Bojan, Anca Simona
FRONTIERS IN CARDIOVASCULAR MEDICINE, 2021, 8
[7] Immune Checkpoint Inhibitors and Immune-Related Adverse Renal Events
Herrmann, Sandra M.
Perazella, Mark A.
KIDNEY INTERNATIONAL REPORTS, 2020, 5 (08): : 1139 - 1148
[8] Efficacy and Safety of Immune Checkpoint Inhibitors in Hematologic Malignancies
Bilgihan, Muhammed Talha
Eryigit, Ayse Nur
Ciftciler, Rafiye
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 (01) : 23 - 31
[9] Immune Checkpoint Inhibitors: The Emerging Cornerstone in Cholangiocarcinoma Therapy?
Gutierrez-Larranaga, Maria
Gonzalez-Lopez, Elena
Roa-Bautista, Adriel
Rodrigues, Pedro M.
Diaz-Gonzalez, Alvaro
Banales, Jesus M.
Lopez-Hoyos, Marcos
Santos-Laso, Alvaro
Crespo, Javier
LIVER CANCER, 2021, 10 (06) : 545 - 560
[10] Myasthenia gravis: An emerging toxicity of immune checkpoint inhibitors
Makarious, D.
Horwood, K.
Coward, J. I. G.
EUROPEAN JOURNAL OF CANCER, 2017, 82 : 128 - 136

← 1 2 3 4 5 →